ClinicalTrials.gg
CompletedNCT06970301Updated Jun 22, 2026

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

A Phase 1 interventional study of glovadalen and Placebo in Healthy Study Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.

02

Conditions studied

  • Healthy Study Participants

Keywords

  • Healthy Study Participants
  • Phase 1
  • ascending dose
  • UCB0022
  • glovadalen
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants must be 18 to 55 years of age inclusive at the time of signing the form (ICF).
  • Participants who are overtly healthy (in the opinion of the investigator) as determined by medical evaluation including medical history (any chronic and acute illness), physical examination, vital signs, 12-lead (ECG), and laboratory tests during the Screening Period. Participants with test results that are outside the specified normal ranges and that are deemed not will be allowed at the discretion of the investigator. If participants have a test result outside the specific range that is deemed clinically significant, repeat of the investigation may be allowed at the discretion of the investigator.
  • For Japanese participants: Participants are of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (participant have all 4 Japanese grandparents born in Japan) and have not had a significant change in lifestyle or diet since leaving Japan.
  • For Chinese participants: Participants are of Chinese descent as evidenced by appearance and verbal confirmation of familial heritage (a participant has all 4 Chinese grandparents born in China) and have not had a significant change in lifestyle or diet since leaving China.
  • For Caucasian participants: Participants are of Caucasian descent as evidenced by appearance and verbal confirmation of familial heritage with all 4 grandparents of Caucasian descent.

Weight

- Participants with body weight ≥45 kilogram (kg) and (BMI) within the range of 18.0 to 30.0 kg/m\^2 (inclusive).

Sex and /barrier requirements

  • Male and female

    1. Male participants must agree to use contraception of the full protocol during the Treatment Period and for 14 days after the final dose of study intervention and refrain from donating sperm during this period.
    2. Female participants are eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

      Not a woman of (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance of the full protocol during the Treatment Period and for at least 14 days after the final dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Participants have any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the participants' ability to participate in this study.
  • Participants have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, cerebrovascular, neurological, or other major disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data in the opinion of the investigator.
  • History of hypertension, hypertensive crisis, hypertensive encephalopathy, or orthostatic hypotension, unless the underlying cause was unequivocally identified and has been removed.
  • History of ischemic stroke, , angina, myocardial infarction, any systemic embolism, any arrythmia, or congestive heart failure
  • Participants have the following liver enzyme test results during the Screening Period or Day -1:

    1. aminotransferase (), aspartate aminotransferase (AST), , or alkaline phosphatase (ALP) >1.0x (ULN), (isolated bilirubin \<1.5xULN is acceptable if fractionated and direct bilirubin \<35%).
    2. Tests that result in ALT, AST, bilirubin, or ALP up to 25% above the exclusion limit may be repeated once for confirmation.
  • Participants have current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
  • Participants have 12-lead with changes considered to be clinically significant (eg, >450 ms in males and >470 ms in females based on average of triplicate ECGs, left bundle branch block, evidence of myocardial ischemia, or second-degree Type II atrioventricular block) during the Screening Period or Day -1.
  • Participants have a history of risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
  • Participants have had any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Participants have had breast cancer within the past 10 years.
  • Participants have a history of a major organ transplant or hematopoietic stem cell/marrow transplant.
  • Participants have a current history of alcohol or drug use disorder, as defined in Version 5, within the last year.
  • Participants have a known to any components of the study intervention as stated in the protocol.
  • Participants have a history of severe allergic reaction that required medical intervention.
  • Participants have clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnea, sore throat, fatigue, anosmia, ageusia) or had a positive SARS CoV 2 test result within the last 4 weeks prior to dosing.
  • Active treatment or a history of glaucoma.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Caucasian)

    Study participants randomized to Cohort 1 (Part A) will receive multiple ascending doses of glovadalen or matching placebo (PBO) at pre-specified time points during the Treatment Period.

    Drug: glovadalen · Other: Placebo

  • Experimental
    Cohort 2 (Japanese)

    Study participants randomized to Cohort 2 (Part B) will receive multiple ascending doses of glovadalen or matching PBO at pre-specified time points during the Treatment Period.

    Drug: glovadalen · Other: Placebo

  • Experimental
    Cohort 3 (Chinese)

    Study participants randomized to Cohort 3 (Part B) will receive multiple ascending doses of glovadalen or matching PBO at pre-specified time points during the Treatment Period.

    Drug: glovadalen · Other: Placebo

Interventions

  • Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.

    Also known as: UCB0022

  • OtherPlacebo

    Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Occurrence of TEAEs (Part A)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) are adverse events not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.

    Time frame: From Baseline to the end of Safety Follow-up Period (up to 49 days)

  2. Occurrence of TEAEs (Part B)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) are adverse events not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.

    Time frame: From Baseline to the end of Safety Follow-up Period (up to 44 days)

Secondary outcomes

  1. Cmax (Part A)

    Cmax: maximum observed plasma concentration

    Time frame: Day 1 in Part A

  2. Cmax,ss (Part A)

    Cmax: maximum observed plasma concentration at steady state condition

    Time frame: From Day 10 to Day 37 in Part A

  3. AUC0-24 (Part A)

    AUC0-24: area under the plasma concentration-time curve from time zero to 24 hours

    Time frame: Day 1 in Part A

  4. AUC0-24,ss (Part A)

    AUC0-24,ss: area under the plasma concentration-time curve from time zero to 24 hours at steady state condition

    Time frame: From Day 10 to Day 37 in Part A

  5. AUC0-t (Part A)

    AUC0-t: area under the plasma concentration-time curve from time zero to the last quantifiable concentration

    Time frame: Day 1 in Part A

  6. AUC0-t,ss (Part A)

    AUC0-t,ss: area under the plasma concentration-time curve from time zero to the last quantifiable concentration at steady state condition

    Time frame: From Day 10 to Day 37 in Part A

  7. Cmax (Part B)

    Cmax: maximum observed plasma concentration

    Time frame: Day 1 in Part B

  8. Cmax,ss (Part B)

    Cmax: maximum observed plasma concentration at steady state condition

    Time frame: From Day 5 to Day 32 in Part B

  9. AUC0-24 (Part B)

    AUC0-24: area under the plasma concentration-time curve from time zero to 24 hours

    Time frame: Day 1 in Part B

  10. AUC0-24,ss (Part B)

    AUC0-24,ss: area under the plasma concentration-time curve from time zero to 24 hours at steady state condition

    Time frame: From Day 5 to Day 32 in Part B

07

Study locations

1 site
  • Up0135 1001
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual patient-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in May 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 14, 2025
StartActual
Apr 28, 2025
Primary completionActual
May 29, 2026
CompletionActual
May 29, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970301
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Apr 28, 2025
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Jun 22, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glovadalen

Start the discussion